Investors

Performance

Revenue ($m)

$2,341m

Operating profit ($m)

$579m

Core¹ operating profit ($m)

$566m

EBITDA² ($m)

$670m

Profit to shareholders ($m)

$431m

Basic earnings per share³ (cents)

183c

Core basic earnings per share³ (cents)

173c

Dividend per share (cents)

50c

Notes

Core results are presented to show the underlying performance of the Group, excluding the exceptional items and other adjustments set out in Note 6 of the Group consolidated financial statements
EBITDA is earnings before interest, tax, depreciation, amortisation and impairment charges
In June 2020, Hikma purchased 12.8 million ordinary shares from Boehringer Ingelheim,
which are being held in treasury. Earnings per share is calculated using the weighted
average number of shares outstanding during the period. Dividend per share is
calculated using the number of shares in issue at 31 December 2020

Five reasons to invest in Hikma

We have a long track record of creating value for our shareholders. By focusing on our strategic priorities and leveraging our strengths, we can build upon our success.

1Unique and diversified business model

Our business is uniquely positioned, with three main business segments. We have a broad and diversified product portfolio and a growing pipeline of new medicines, that are sold in the retail and hospital markets.

2Strong market position

We are the third largest generic injectable manufacturer and a top ten generic company in the US. In MENA, we are one of the largest pharmaceutical companies with very strong brand awareness.

3Commitment to quality

We have built our reputation on manufacturing high-quality medicines. Quality is embedded in our people, our relationships and our thinking. Our excellent track record of regulatory compliance has made us the partner of choice for our customers and patients

4Large and growing pipeline

We have a large and growing pipeline, with an increasing proportion of differentiated and complex products. We complement our internal R&D with partnerships and M&A.

5Strong balance sheet and cash generation

We consistently generate strong cash flow. Our disciplined approach to cash management and acquisitions ensures we maintain a strong balance sheet and gives us the financial flexibility to support future growth.